Evidence map›Paper›PMID 31767633›Full record

ArticleMolecular and cellular biology2020

FOXM1-Activated LINC01094 Promotes Clear Cell Renal Cell Carcinoma Development via MicroRNA 224-5p/CHSY1.

Yufeng Jiang, Haimin Zhang, Wei Li, Yang Yan, Xudong Yao, Wenyu Gu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. The Characterization and Differential Analysis of mAnimals : an open access journal from MDPI · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yufeng JiangDepartment of Urology, Chongming Branch, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Haimin ZhangDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China zhm1064@163.com.
Wei LiDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Yang YanDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Xudong YaoDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Wenyu GuDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Tongji University · CNShanghai Tenth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is regarded as the most aggressive subtype of RCC, with high rates of metastasis and recurrence. An extensive body of studies had proved long noncoding RNAs (lncRNAs) play pivotal parts in the development and evolution of diverse malignant tumors. However, the potential of LINC01094 in ccRCC tumorigenesis is still unexplored. In the present research, with the aid of the TCGA database, we found that LINC01094 was highly expressed in ccRCC tissues. Upregulation of LINC01094 was also confirmed in ccRCC cell lines, and functional experiments delineated that LINC01094 knockdown led to inhibition on ccRCC cell growth and metastasis. Moreover, LINC01094 was activated by FOXM1 at the transcriptional level. Further assay demonstrated that LINC01094 worked as a sponge of microRNA 224-5p (miR-224-5p) and CHSY1 was a miR-224-5p-targeted mRNA. Further, we verified that LINC01094 acted as a competing endogenous RNA in ccRCC to regulate CHSY1 expression via competitively bind to miR-224-5p. Lastly, our results expounded that LINC01094 exerted its tumor-promoting performance in ccRCC development through miR-224-5p/CHSY1 regulatory axis, which shed light on the molecular mechanism underlying LINC01094 in ccRCC and opened a new prospective for the treatment of ccRCC.

Indexed as

AnimalsCarcinoma, Renal CellCell Line, TumorFemaleForkhead Box Protein M1Gene Expression Regulation, NeoplasticGlucuronosyltransferaseHumansKidney NeoplasmsMice, Inbred BALB CMice, NudeMicroRNAsMultifunctional EnzymesN-AcetylgalactosaminyltransferasesRNA, Long NoncodingCHSY1 protein, humanForkhead Box Protein M1FOXM1 protein, humanGlucuronosyltransferaseMicroRNAsMIRN224 microRNA, humanMultifunctional EnzymesN-AcetylgalactosaminyltransferasesRNA, Long NoncodingccRCCCHSY1FOXM1LINC01094miR-224-5p

Identifiers

PMID31767633
PMCPMC6965037
OpenAlexW2991318399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.